Cargando…

QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC

BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Polskin, Lily, Pillai, Valentina, Vera, Elizabeth, Acquaye, Alvina, Briceno, Nicole, Choi, Anna, Christ, Alexa, Grajkowska, Ewa, Jammula, Varna, Leeper, Heather, Levine, Jason, Lindsley, Matthew, Reyes, Jennifer, Roche, Kayla, Rogers, James, Timmer, Michael, Boris, Lisa, Burton, Eric, Lollo, Nicole, Panzer, Marissa, Penas-Prado, Marta, Theeler, Brett, Wu, Jing, Gilbert, Mark, Armstrong, Terri, King, Amanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598910/
http://dx.doi.org/10.1093/neuonc/noab196.757
_version_ 1784600830300651520
author Polskin, Lily
Pillai, Valentina
Vera, Elizabeth
Acquaye, Alvina
Briceno, Nicole
Choi, Anna
Christ, Alexa
Grajkowska, Ewa
Jammula, Varna
Leeper, Heather
Levine, Jason
Lindsley, Matthew
Reyes, Jennifer
Roche, Kayla
Rogers, James
Timmer, Michael
Boris, Lisa
Burton, Eric
Lollo, Nicole
Panzer, Marissa
Penas-Prado, Marta
Theeler, Brett
Wu, Jing
Gilbert, Mark
Armstrong, Terri
King, Amanda
author_facet Polskin, Lily
Pillai, Valentina
Vera, Elizabeth
Acquaye, Alvina
Briceno, Nicole
Choi, Anna
Christ, Alexa
Grajkowska, Ewa
Jammula, Varna
Leeper, Heather
Levine, Jason
Lindsley, Matthew
Reyes, Jennifer
Roche, Kayla
Rogers, James
Timmer, Michael
Boris, Lisa
Burton, Eric
Lollo, Nicole
Panzer, Marissa
Penas-Prado, Marta
Theeler, Brett
Wu, Jing
Gilbert, Mark
Armstrong, Terri
King, Amanda
author_sort Polskin, Lily
collection PubMed
description BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS: Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS: The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION: Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology
format Online
Article
Text
id pubmed-8598910
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-85989102022-01-05 QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC Polskin, Lily Pillai, Valentina Vera, Elizabeth Acquaye, Alvina Briceno, Nicole Choi, Anna Christ, Alexa Grajkowska, Ewa Jammula, Varna Leeper, Heather Levine, Jason Lindsley, Matthew Reyes, Jennifer Roche, Kayla Rogers, James Timmer, Michael Boris, Lisa Burton, Eric Lollo, Nicole Panzer, Marissa Penas-Prado, Marta Theeler, Brett Wu, Jing Gilbert, Mark Armstrong, Terri King, Amanda Neuro Oncol 26th Annual Meeting & Education Day of the Society for Neuro-Oncology BACKGROUND: Primary CNS tumors are associated with uncertainty likely contributing to mood disturbance that is common throughout the disease trajectory. The intersection of the COVID-19 pandemic with a CNS tumor diagnosis may further impact the anxiety/depression experienced in this population. This study assessed key anxiety/depression symptoms in patients with CNS tumors prior to and during the COVID year. METHODS: Patient reported outcomes (PROs), including the PROMIS Anxiety and Depression Short Forms and EQ-5D-3L, were collected at the time of clinical or telehealth evaluation from the COVID year (March 2020-February 2021) and were compared to assessments through February 2020 (a NOB-normative sample), reflecting what we would typically see in our regular clinic evaluations. RESULTS: The COVID sample (N = 178) was primarily White (82%), male (55%), median age of 45 (range 18–79), and KPS ³ 90 (50%). The majority had high grade (70%) brain (83%) tumors with ³ 1 prior recurrence (60%) and 25% were on active treatment. Visits were primarily conducted via telehealth (64%) and 20% had progression at assessment. Compared to the NOB-normative sample, patients reported significantly higher depression scores (moderate-severe, 17% vs. 12%, p < 0.05), but not anxiety (18% vs. 16%). Eleven percent reported both moderate-severe anxiety and depressive symptoms (8% pre-COVID). Overall health assessed by the EQ-5D-3L was similar to the normative sample in all dimensions, apart from impact of moderate/extreme mood disturbance, which was more prevalent in the COVID year (53% vs. 43%, p < 0.05%). CONCLUSION: Patients with CNS tumors are at risk for significant symptoms of depression and anxiety; this risk was heightened during the COVID year. Further evaluation of clinical factors associated with risk are underway. These findings highlight the need for assessments and interventions that can be administered via telehealth to address the mental health needs of this vulnerable population. Radiobiology Oxford University Press 2021-11-12 /pmc/articles/PMC8598910/ http://dx.doi.org/10.1093/neuonc/noab196.757 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_modelThis article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
spellingShingle 26th Annual Meeting & Education Day of the Society for Neuro-Oncology
Polskin, Lily
Pillai, Valentina
Vera, Elizabeth
Acquaye, Alvina
Briceno, Nicole
Choi, Anna
Christ, Alexa
Grajkowska, Ewa
Jammula, Varna
Leeper, Heather
Levine, Jason
Lindsley, Matthew
Reyes, Jennifer
Roche, Kayla
Rogers, James
Timmer, Michael
Boris, Lisa
Burton, Eric
Lollo, Nicole
Panzer, Marissa
Penas-Prado, Marta
Theeler, Brett
Wu, Jing
Gilbert, Mark
Armstrong, Terri
King, Amanda
QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title_full QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title_fullStr QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title_full_unstemmed QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title_short QOLP-37. MOOD DISTURBANCE IN PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) TUMORS DURING THE COVID-19 PANDEMIC
title_sort qolp-37. mood disturbance in patients with central nervous system (cns) tumors during the covid-19 pandemic
topic 26th Annual Meeting & Education Day of the Society for Neuro-Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598910/
http://dx.doi.org/10.1093/neuonc/noab196.757
work_keys_str_mv AT polskinlily qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT pillaivalentina qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT veraelizabeth qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT acquayealvina qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT bricenonicole qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT choianna qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT christalexa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT grajkowskaewa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT jammulavarna qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT leeperheather qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT levinejason qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT lindsleymatthew qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT reyesjennifer qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT rochekayla qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT rogersjames qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT timmermichael qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT borislisa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT burtoneric qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT lollonicole qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT panzermarissa qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT penaspradomarta qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT theelerbrett qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT wujing qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT gilbertmark qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT armstrongterri qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic
AT kingamanda qolp37mooddisturbanceinpatientswithcentralnervoussystemcnstumorsduringthecovid19pandemic